対面形式の対話型ディスカッション

業界の専門家や同業者と、研究の進捗状況や動向、直面する課題などについて、詳細なディスカッションを行うことができます。

対話型ディスカッション・グループは、潜在的な協力者とのつながりを作るのに欠かせない役割を果たします。また、ご自分の研究事例をシェアしたり、同業者とアイデアを出し合ったり、グループでの問題解決の取り組みに参加したりすることができる機会となっています。

8月7日 水曜日, 10:10 AM - 10:55 AM

Breakout Discussions with Networking Coffee Break

TRACK: BISPECIFIC ANTIBODIES FOR CANCER IMMUNOTHERAPY

IN-PERSON BREAKOUT TABLE 1: Challenges and Advancements with Bi and Multi-Specific Antibodies

Moderator:  Mark A Tornetta, Vice President, Biologics Discovery, Tavotek Biotherapeutics

• Challenges and solutions in bi- and multi-specific antibody design
• CMC considerations for bi- and multi-specifics
• Advancements in solid tumors and future directions

TRACK: ADVANCES IN CAR T THERAPY

Moderator:  Julia A Coronella, PhD, VP Immuno Oncology, Immuno Oncology, Poseida Therapeutics Inc

• Considerations for TSCM-based CAR T products
• Autologous vs allogenic therapy
• Viral vs non-viral methodologies

TRACK: THERAPEUTIC CANCER VACCINES

Moderator: Marion Curtis, PhD, Assistant Professor, Immunology, Mayo Clinic

• What are the most promising strategies to identify and target tumor-specific antigens using cancer vaccines?
• What are the most effective vaccine delivery platforms for cancer therapy?--
• What role do combination therapies play in overcoming immunosuppression and maximizing the effectiveness of cancer vaccines?
• How can cancer vaccines be successfully integrated into standard of care cancer treatment?

TRACK: EMERGING TECH FOR IO TARGETING & DISCOVERY

Moderator: Theresa M. LaVallee, PhD, Chief Development Officer, Coherus Biosciences

• Approaches to characterize PD-1 resistance
• Applications of PD-1 resistance characterization for target discovery 
• Uncovering novel and next-gen combination treatment approaches through PD-1 findings

Moderator: Nir Chetrit, PhD, Associate Researcher, Weill Cornell Medicine

• Modulating the tumor-supporting functions of TAMs: current approaches & challenges
• Novel strategies and technologies to overcome limitations of TAM reprogramming
• Scalable TME models and platforms for high-throughput discovery

TRACK: EMERGING CELL-BASED IMMUNOTHERAPIES

Moderator: Madan H. Jagasia, MS, Chief Executive Officer, R&D, Obsidian Therapeutics

• Currently available non-engineered TIL cell therapy requires use of high-dose IL2, which has well-described high-grade toxicity that limits patient eligibility
• Novel approaches are needed to improve the safety of TIL cell therapy to enable a broader patient population to benefit
• Discussion will focus around existing approaches to improve safety as well as potential avenues to explore in future trials

Moderator: Nicholas A Zorko, PhD, Assistant Professor, Hematology & Oncology & Transplant, University Of Minnesota Twin Cities

• Challenges with NK cell therapy development
• Pros and cons of NK approaches compared to other cell-based therapeutics
• Applications of NK therapies to solid tumor indications
• Future directions of NK therapies

TRACK: TUMOR MICROENVIRONMENT

Moderator: Thierry Guillaudeux, PhD, CSO, Kineta, Inc.

• What are the major drivers of immunosuppression in the tumor microenvironment?
• What are the strategies to overcome immunosuppression?
• What are the promising new targets?
• Which combination strategies should be considered to restore an effective antitumor immune response?

Moderator: Jason Yu, PhD, Senior Postdoctoral Associate, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

• What aspects of the TME require ex vivo modeling?
• What are the challenges in modeling tumor immune responses?
• What are the unique advantages of ex vivo TME models?
• How do we advance ex vivo TME models for drug discovery and mechanistic studies?